PRTG

Portage Biotech Inc. [PRTG] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

PRTG Stock Summary

Top 10 Correlated ETFs

PRTG


Top 10 Correlated Stocks

PRTG


In the News

09:02 01 Apr 2023 PRTG

New Strong Buy Stocks for January 26th

FYBR, SPPJY, KMTUY, PRTG and ASML have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.

07:32 01 Apr 2023 PRTG

New Strong Buy Stocks for January 20th

NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.

10:32 01 Apr 2023 PRTG

New Strong Buy Stocks for November 1st

FFNW, PTEN, PRTG, NTNX and GAMB have been added to the Zacks Rank #1 (Strong Buy) List on November 1, 2022.

11:37 01 Apr 2023 PRTG

Does Portage Biotech Inc. (PRTG) Have the Potential to Rally 206% as Wall Street Analysts Expect?

The mean of analysts' price targets for Portage Biotech Inc. (PRTG) points to a 206.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

04:07 01 Apr 2023 PRTG

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

Portage Biotech Inc (NASDAQ: PRTG) acquired the remaining 22% stake in its invariant natural killer T cell (iNKT agonist) platform and now wholly owns the worldwide rights to its small molecule iNKT agonists, including lead programs PORT-2 and PORT-3.  The platform was acquired.

04:53 01 Apr 2023 PRTG

Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference

WESTPORT, Conn., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that Chief Executive Officer, Dr. Ian Walters, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021. Dr. Walters will give an overview of Portage's pipeline and status of current programs, including the company's lead invariant natural killer T cell (iNKT) agonists, PORT-2 and PORT-3.

08:00 01 Apr 2023 PRTG

Portage Biotech Announces Participation in September 2021 Investor Conferences

WESTPORT, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that as part of its commitment to investor outreach, management will be participating in the following investor conferences in September 2021.

08:00 01 Apr 2023 PRTG

Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year

- $29 million raised during quarter with broad institutional support

08:00 01 Apr 2023 PRTG

Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)

WESTPORT, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the first patient has been dosed in the Oxford-led IMP-MEL study, a Phase 1/2, open-label, dose-escalation and randomized expansion clinical trial assessing the safety, tolerability and efficacy of PORT-2, a liposome formulation of the invariant natural killer T-cell (iNKT) agonist IMM60 developed for the treatment of solid tumors.

09:00 01 Apr 2023 PRTG

Portage Biotech Added to Russell 2000(R) Index

Westport, Connecticut--(Newsfile Corp. - June 29, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the Company has been added to the Russell 2000 Index at the conclusion of the 2021 Russell Indexes annual reconstitution, effective after the U.S. market opened on June 28. "Inclusion in the Russell 2000 index marks another key milestone for Portage,...

PRTG Financial details

Company Rating
Neutral
Market Cap
53.78M
Income
-13.68M
Revenue
0
Book val./share
9.92
Cash/share
0.77
Dividend
-
Dividend %
-
Employees
6
Optionable
No
Shortable
Yes
Earnings
01 Mar 2023
P/E
-3.85
Forward P/E
-
PEG
1.13
P/S
-
P/B
0.31
P/C
4.01
P/FCF
-5.94
Quick Ratio
5.75
Current Ratio
6.41
Debt / Equity
0.25
LT Debt / Equity
-
-
-
EPS (TTM)
-0.89
EPS next Y
-
EPS next Q
-
EPS this Y
-4.44%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
633.33%
-
-
-
-
SMA20
-24.32%
SMA50
-47.96%
SMA100
-58.27%
Inst Own
0.06%
Inst Trans
0.02%
ROA
-6%
ROE
-9%
ROC
-0.08%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
17.4M
Shs Float
9.84M
-
-
-
-
Target Price
19.5
52W Range
2.34-11.99
52W High
-71.91%
52W Low
+54.5%
RSI
45.95
Rel Volume
0.64
Avg Volume
39.58K
Volume
25.28K
Perf Week
17.49%
Perf Month
-25.18%
Perf Quarter
-53.18%
Perf Half Y
-50.48%
-
-
-
-
Beta
115.11
-
-
Volatility
0.17%, 0.43%
Prev Close
3%
Price
3.09
Change
14.44%

PRTG Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-03-31

Metric History 2018-03-312019-03-312020-03-312021-03-31 2022-03-31
Revenue per share
00000
Net income per share
46.21-0.55-0.49-1.35-1.29
Operating cash flow per share
-0.4-0.18-0.34-0.37-0.52
Free cash flow per share
-0.4-0.18-0.34-0.37-0.52
Cash per share
2.831.30.290.241.79
Book value per share
3.5920.688.818.659.28
Tangible book value per share
3.59-2.52-1.38-1.120.36
Share holders equity per share
3.5920.688.818.659.28
Interest debt per share
0.10.780.390.170
Market cap
20.08M45.31M99.66M328.17M85.8M
Enterprise value
12.8M42.8M100.17M327.2M62.45M
P/E ratio
0.16-17.19-18.69-20.73-5.09
Price to sales ratio
00000
POCF ratio
-18.72-52.81-26.83-76.6-12.69
PFCF ratio
-18.72-52.81-26.83-76.6-12.69
P/B Ratio
2.090.451.033.230.71
PTB ratio
2.090.451.033.230.71
EV to sales
00000
Enterprise value over EBITDA
0.1-16.81-38.36-24.49-5.01
EV to operating cash flow
-11.93-49.89-26.97-76.38-9.23
EV to free cash flow
-11.93-49.89-26.97-76.38-9.23
Earnings yield
6.16-0.06-0.05-0.05-0.2
Free cash flow yield
-0.05-0.02-0.04-0.01-0.08
Debt to equity
0.040.250.290.270.24
Debt to assets
0.040.140.160.160.15
Net debt to EBITDA
-0.060.98-0.190.071.87
Current ratio
59.973.651.481.5431.71
Interest coverage
-69.59-31.41-10.73-70.28-362.51
Income quality
-0.010.330.70.270.35
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00.930.930.920.83
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
61.1115.959.8316.216.42
ROIC
0.43-0.02-0.05-0.08-0.14
Return on tangible assets
12.37-0.2-0.43-1.12-0.5
Graham Net
2.69-3.91-2.22-2.04-0.44
Working capital
7.49M4.76M1.23M1.74M24.05M
Tangible asset value
9.62M-12.16M-15.07M-13.11M4.72M
Net current asset value
7.23M-18.61M-23.74M-22.31M-4.4M
Invested capital
0.020.040.040.020
Average receivables
22.22K41.5K57.5K371.5K446K
Average payables
118.03K257.5K365.5K228K150.5K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
12.86-0.03-0.06-0.16-0.14
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q3

Metric History 2021-09-302021-12-312022-06-302022-09-30 2022-12-31
Revenue per share
00000
Net income per share
-0.22-0.26-0.13-0.06-0.44
Operating cash flow per share
-0.1-0.12-0.16-0.15-0.16
Free cash flow per share
-0.1-0.12-0.16-0.15-0.16
Cash per share
2.041.921.590.90.77
Book value per share
9.549.439.0410.669.92
Tangible book value per share
0.970.810.32-0.7-1.24
Share holders equity per share
9.549.439.0410.669.92
Interest debt per share
00000
Market cap
270.91M143.18M93.19M114.18M90.12M
Enterprise value
243.65M117.58M72.01M99.14M77.02M
P/E ratio
-22.77-10.19-13.47-30.08-3.01
Price to sales ratio
00000
POCF ratio
-212.48-86.36-42.83-45.45-33.33
PFCF ratio
-212.48-86.36-42.83-45.4-33.33
P/B Ratio
2.131.140.770.640.53
PTB ratio
2.131.140.770.640.53
EV to sales
00000
Enterprise value over EBITDA
-70.19-34.64-16.9-28.38-14.71
EV to operating cash flow
-191.09-70.92-33.09-39.47-28.48
EV to free cash flow
-191.09-70.92-33.09-39.42-28.48
Earnings yield
-0.01-0.02-0.02-0.01-0.08
Free cash flow yield
0-0.01-0.02-0.02-0.03
Debt to equity
0.20.190.230.220.25
Debt to assets
0.130.120.140.180.2
Net debt to EBITDA
7.857.544.974.312.5
Current ratio
21.3141.3111.7311.986.41
Interest coverage
-475.71-4.17K-194.62-405.89-95.18
Income quality
0.430.471.342.320.36
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.810.820.830.870.9
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
6.927.475.133.699.9
ROIC
-0.02-0.03-0.01-0.01-0.04
Return on tangible assets
-0.08-0.1-0.05-0.04-0.35
Graham Net
0.220.1-0.49-1.38-1.68
Working capital
27.3M25.64M21.14M15.74M13.11M
Tangible asset value
12.87M10.85M4.3M-11.64M-21.15M
Net current asset value
3.79M2.03M-4.76M-21.55M-26.85M
Invested capital
00000
Average receivables
816K374.5K0545.5K832K
Average payables
802.5K238.5K01.68M1.92M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.02-0.03-0.01-0.01-0.04
Capex per share
00000

PRTG Frequently Asked Questions

What is Portage Biotech Inc. stock symbol ?

Portage Biotech Inc. is a VG stock and trading under the symbol PRTG

Is Portage Biotech Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $19.5. The lowest prediction is $18 and the highest is $21

What is PRTG stock prediction ?

What is Portage Biotech Inc. stock quote today ?

Portage Biotech Inc. stock price is $3.09 today.

Is Portage Biotech Inc. stock public?

Yes, Portage Biotech Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap